Attention Deficit/Hyperactivity Disorder (ADHD) Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2022-2032) | Key Companies – Otsuka, BioLite, Shire, Hisamitsu

Attention Deficit/Hyperactivity Disorder (ADHD) Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2022-2032) | Key Companies - Otsuka, BioLite, Shire, Hisamitsu
Delveinsight Business Research LLP
As per DelveInsight, the Attention Deficit/Hyperactivity Disorder (ADHD) Market is anticipated to grow in the coming years owing to the rise in the number of prevalent cases and the launch of better treatment options in the market.

There is a significant need for non-stimulant ADHD treatments in the marketplace, especially in light of recent regulatory oversight of abuse of currently approved treatments. The market possesses few alternatives for non-stimulants to fulfill the unmet need to overcome drug abuse. Considering the present scenario, the market expects newer non-stimulant drugs in the near future.

To accomplish and meet these unmet needs, several companies are developing drugs in the market, which includes companies like KemPharm, Supernus Pharmaceuticals, Sumitomo Dainippon Pharma, Otsuka Pharmaceuticals, AEVI Genomic Medicine, Amarantus Bioscience, NLS Pharma, RespireRx Pharmaceuticals and more, that will help the patients in the coming future.

DelveInsight’s “Attention Deficit/Hyperactivity Disorder (ADHD) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Attention Deficit/Hyperactivity Disorder market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Attention Deficit/Hyperactivity Disorder market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Attention DeficitHyperactivity Disorder (ADHD) Market

Attention Deficit/Hyperactivity Disorder (ADHD): An Overview

ADHD is one of the most common neurodevelopmental disorders of childhood. It is usually first diagnosed in childhood and often lasts into adulthood. Children with ADHD may have trouble paying attention, control impulsive behaviors (may act without thinking about the result), or be overly active. The symptoms continue, can be severe, and can cause difficulty at school, at home, or with friends.

It’s not clear what causes the brain differences of ADHD. There’s strong evidence that ADHD is mostly inherited. Many kids who have ADHD have a parent or relative with it. Kids also can be more at risk for it if they were born early, are exposed to environmental toxins, or their mothers used drugs during pregnancy. In adults, the symptoms of ADHD are more difficult to define. This is largely due to a lack of research into adults with ADHD.

Treatment for ADHD usually includes Medicine. This activates the brain’s ability to pay attention, slow down, and use more self-control, Behavior therapy. Therapists can help kids develop the social, emotional, and planning skills that are lagging with ADHD, Parent coaching. Through coaching, parents learn the best ways to respond to behavior problems that are part of ADHD.

Attention Deficit/Hyperactivity Disorder (ADHD) Market Key Facts

  • Among the European countries, France had the highest diagnosed prevalent population of ADHD, with 2,387,148 cases, followed by Italy in 2017. On the other hand, Germany had the lowest diagnosed prevalent population in 2017.

  • As per the country analysis, the US had the highest number of cases, followed by Japan and other European countries.

  • Japan was estimated to account for 3,138,319 diagnosed prevalent cases of ADHD in 2017.

  • The Centers for Disease Control and Prevention (CDC) suggests that the estimated number of children diagnosed with ADHD, according to a national 2016 parent survey, were 1 is 6.1 million (9.4%). This number includes 388,000 children aged 2–5 years, 4 million children aged 6–11 years and 3 million children aged 12–17 years. Furthermore, the CDC also highlights the fact that boys are more likely to be diagnosed with ADHD than girls (12.9% compared to 5.6%).

Attention Deficit/Hyperactivity Disorder (ADHD) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Attention Deficit/Hyperactivity Disorder market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Attention Deficit/Hyperactivity Disorder market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Attention Deficit/Hyperactivity Disorder (ADHD) Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Attention Deficit/Hyperactivity Disorder (ADHD) Epidemiology, Segmented as –

  • Total Diagnosed Prevalent Cases of ADHD in the 7MM [2019–2032]

  • Gender-specific Diagnosed Prevalent Cases of ADHD in Children in the 7MM [2019–2032]

  • Gender-specific Diagnosed Prevalent Cases of ADHD in Adults in the 7MM [2019–2032]

  • Subtype-specific Diagnosed Prevalent Cases of ADHD in the 7MM [2019–2032]

Attention Deficit/Hyperactivity Disorder (ADHD) Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Attention Deficit/Hyperactivity Disorder market or expected to be launched during the study period. The analysis covers the Attention Deficit/Hyperactivity Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Attention Deficit/Hyperactivity Disorder pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Attention Deficit/Hyperactivity Disorder Market Will Evolve and Grow by 2032 @

Attention Deficit/Hyperactivity Disorder (ADHD) Therapeutics Analysis

Several major pharma and biotech giants are developing therapies for Attention-Deficit Hyperactivity Disorder. Currently, Otsuka Pharmaceutical is leading the therapeutics market with its Attention Deficit Hyperactivity Disorder drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Attention-deficit/hyperactivity disorder (ADHD) Therapeutics Market Include:

ABVC BioPharma, AgoneX Biopharmaceuticals, Arbor Pharma, BioLite, Inc., Cennerv Pharma, Cingulate, Curemark, Ensysce Biosciences, EnvisionRx, Highland Therapeutics, Hisamitsu Pharmaceutical Co, INVENT Pharmaceuticals, Kempharm, Materia Medica Holding, Neos Therapeutics, NeuroNascent, Inc., NLS Pharmaceutics Ltd, Otsuka Pharmaceutical, RespireRx Pharmaceuticals, Rhodes Pharmaceuticals, Shire, Supernus Pharmaceuticals, Tris Pharma, Inc., and many more.

Attention Deficit Hyperactivity Disorder Emerging and Marketed Drugs Covered in the Report Include:

  • Centanafadine: Otsuka Pharmaceutical

  • PDC-142: BioLite, Inc.

  • Mydayis: Shire

  • Daytrana: Hisamitsu Pharmaceutical Co

  • Adzenys: Neos Therapeutics

  • Cotempla XR-ODT: Neos Therapeutics

  • Aptensio XR: Rhodes Pharmaceuticals

  • Dyanavel XR: Tris Pharma

  • Jornay: Highland Therapeutics

  • EVEKEO ODT (Amphetamine Sulfate): Arbor Pharma

  • SPN-812: Supernus Pharmaceuticals

  • KP484: KemPharm Inc.

And many more

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Attention Deficit/Hyperactivity Disorder Competitive Intelligence Analysis

4. Attention Deficit/Hyperactivity Disorder Market Overview at a Glance

5. Attention Deficit/Hyperactivity Disorder Disease Background and Overview

6. Attention Deficit/Hyperactivity Disorder Patient Journey

7. Attention Deficit/Hyperactivity Disorder Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Attention Deficit/Hyperactivity Disorder Treatment Algorithm, Current Treatment, and Medical Practices

9. Attention Deficit/Hyperactivity Disorder Unmet Needs

10. Key Endpoints of Attention Deficit/Hyperactivity Disorder Treatment

11. Attention Deficit/Hyperactivity Disorder Marketed Products

12. Attention Deficit/Hyperactivity Disorder Emerging Drugs and Latest Therapeutic Advances

13. Attention Deficit/Hyperactivity Disorder Seven Major Market Analysis

14. Attribute Analysis

15. Attention Deficit/Hyperactivity Disorder Market Outlook (In US, EU5, and Japan)

16. Attention Deficit/Hyperactivity Disorder Access and Reimbursement Overview

17. KOL Views on the Attention Deficit/Hyperactivity Disorder Market

18. Attention Deficit/Hyperactivity Disorder Market Drivers

19. Attention Deficit/Hyperactivity Disorder Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @


Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @ Pharmaceutical Partner Identification Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States